Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-κB Pathway, Thereby Reversing the Drug Resistance of Hepatocellular Carcinoma to Sorafenib

Activation of the cellular signaling pathways can induce sorafenib-resistant hepatocellular carcinoma (HCC R ). In this work, the PI3K/mTOR inhibitor GSK1059615 inhibited the proliferation and invasion of HCC R cells. PLGA-PEG-mal diblock copolymer was used to load GSK1059615 and sorafenib, and the vector was further modified with GPC3 antibody (hGC33) to obtain hGC33-modified GSK1059615 and sorafenib-loaded nanoparticles (Ab-G/S-NP). Ab-G/S-NP regulated the activation of cellular signaling pathways in HCC R cells by inhibiting the expression and activation of NF- κ B and downregulating the level of programmed cell death 1 ligand 1(PD-L1) to reverse drug resistance of HCC R cells to sorafenib. These findings deserve further study in the combined treatment of HCC R cells with GSK1059615 in vivo to develop a more effective treatment of sorafenib-resistant cancers.